Wegovy names: what the brand, generic and other drug names actually mean

You search 'semaglutide' and get four different product names back, here's why

Picture this: you've just left a GP appointment, been told semaglutide might help with your weight, and you've gone straight to a search engine. Four names come back: Wegovy, Ozempic, Rybelsus, Wegovy tablets. It's not immediately obvious whether those are competing products or the same thing repackaged.

Semaglutide is the international non-proprietary name (INN), the molecule's official, generic identity, the name a pharmacist or prescriber uses in clinical documents regardless of which company made it. Think of it the way you'd think of paracetamol: one generic name, several brand-name products sitting above it. The full picture of semaglutide as a medicine covers its mechanism, how it works on GLP-1 receptors, and its clinical history.

Novo Nordisk, the Danish pharmaceutical company that developed the molecule, markets it under multiple brand names for different approved uses. That's not unusual in pharmaceuticals, the same compound can earn separate licences for separate conditions, each with its own dosing, formulation and brand identity.

What matters practically: when you see "semaglutide" on a prescription, the pharmacist looks at the dose and formulation to know which product to dispense. The name Wegovy specifically means the weight-management version, and that licence matters. An exploration of semaglutide's various brand names lays this out in more detail if you want to go deeper on each one.

Wegovy versus Ozempic: same molecule, different job

This is the question our prescribers hear most weeks, so it's worth being direct. Yes, Wegovy and Ozempic both contain semaglutide. No, they are not interchangeable in the UK.

Ozempic is licensed in the UK for type 2 diabetes. It comes in doses up to 2mg and its licence covers blood-sugar management, with cardiovascular risk reduction as an additional indication. The MHRA has not approved Ozempic for weight management. Prescribing it off-licence for that purpose falls outside normal UK clinical practice and is not something regulated online pharmacies do routinely.

Wegovy injection is licensed for weight management in adults with a BMI of 30 or above, or 27 and above with at least one weight-related health condition. It's the same semaglutide molecule but at a higher maintenance dose (up to 2.4mg weekly, with a new 7.2mg option approved by the MHRA in April 2026) and a separate clinical trial programme (STEP 1 and others) underpins that licence. The Wegovy treatment page covers the licensed dosing pathway and eligibility in full.

The NHS is equally clear on this: the NHS medicines information for semaglutide distinguishes the products by brand and by licensed use. Using the wrong brand for the wrong condition isn't just a naming technicality, it's a clinical one.

Wegovy tablets, Rybelsus and the oral semaglutide naming puzzle

On 11 June 2026 the MHRA approved Wegovy tablets, the first oral GLP-1 medicine licensed for weight management in the UK, and the first in Europe. Same molecule, completely different formulation: semaglutide is combined with an absorption enhancer called SNAC so it can survive the stomach and reach the bloodstream when swallowed. The tablet sits on the bedside table or in a kitchen drawer rather than the fridge door, which matters for anyone whose routine makes refrigerated injections awkward.

The dosing schedule runs 1.5mg, 4mg, 9mg and up to a 25mg maintenance dose, taken once daily, first thing, on an empty stomach with a small amount of plain water, at least 30 minutes before eating or drinking anything else. That schedule is entirely separate from Rybelsus, which also contains oral semaglutide but at 3mg, 7mg and 14mg doses, licensed only for type 2 diabetes. Those tablet strengths are not weight-management doses and should not be confused with the Wegovy tablet ladder. A page on Wegovy's generic name unpacks this further.

The OASIS 4 phase 3 trial, which supported the UK approval, reported around 13.6% average weight loss over 64 weeks compared with around 2.4% on placebo, among participants who adhered fully, the figure was closer to 17%. Those results are meaningful, and they're what the MHRA weighed when granting the licence.

For anyone comparing the injectable and tablet options, or trying to work out which semaglutide product applies to their situation, this guide to semaglutide's drug names sits alongside a broader look at the other names semaglutide goes by in clinical and everyday use.

Why the name on the packaging is a clinical detail, not just a label

Brand names on medicines exist partly for commercial reasons, but in practice they carry real clinical meaning: the approved indication, the licensed dose range, the trial evidence, the regulatory conditions. When a prescriber writes Wegovy rather than semaglutide on a prescription, they're specifying which product and which clinical context applies.

Online, the names get muddled, search results mix brand names, generic names and US names freely. Zepbound, for instance, appears often in weight-loss searches: it's the US brand name for tirzepatide, a different molecule altogether, and it doesn't exist as a UK product. In the UK, tirzepatide is sold as Mounjaro.

The practical takeaway: if you're looking at weight management options and want to understand which semaglutide product, which dosing route and which clinical pathway applies to your situation, a prescriber is the right person to answer that. Our weight-loss treatment page explains the options we offer and how the free consultation works. You can also browse our treatment overview if you're still at the comparing-options stage, or read more about semaglutide's names across products before you decide.

Every consultation at nume is reviewed by a GPhC-registered Independent Prescriber (a named clinician, not automated software) who looks at your full picture before any prescription is issued. That's the step that turns a brand name into a treatment plan.